Minimally invasive surgical device manufacturer LAGIS is scheduled to officially list on the Taipei Exchange (TPEx) in mid-December and will hold its pre-listing earnings conference today (Dec. 18). Chairman Chen Cheng-Hung said yesterday (Dec. 17) that in addition to steady growth from existing customers, the company continues to expand its customer base and is actively seeking entry opportunities in the U.S. market, with discussions underway with potential clients. With multiple growth drivers advancing in parallel, LAGIS aims to achieve double-digit percentage revenue growth next year.
LAGIS provides comprehensive minimally invasive medical device solutions through in-house R&D, manufacturing, and its proprietary brand. Its self-owned LAGIS product line has successfully penetrated international healthcare systems, with trocar products commanding nearly 30% market share in Taiwan, ranking first among domestic brands. Chen noted that the company’s core competitive advantage lies in having built its own brand over the past 20 years. Its products are now sold in more than 50 countries, with Japan as the largest market, accounting for approximately 25% of revenue, followed by Taiwan and Europe.
Trocar systems remain the company’s flagship products. Among recent highlights, the single-port multi-channel trocar system allows multiple surgical instruments to be introduced through a single incision, making it suitable for natural orifice surgeries such as transanal or transvaginal procedures. This approach leaves no visible external wounds, shortens postoperative recovery time, and integrates seamlessly with the da Vinci robotic system, significantly enhancing surgical efficiency. Electrified surgical instruments have also gained strong clinical recognition. The bipolar series combines coagulation and cutting functions, reducing instrument changes and minimizing thermal tissue damage, while the monopolar series is widely used across various procedures for its high power output and strong cost-performance ratio.
General Manager Chen Cheng-Hsiung said the company launches at least three to four new products each year. New products introduced this year include endoscopic surgical instruments (sterile pouch packaging), third-generation trocars (6 mm), and transanal surgical access platforms with expanded specifications. Planned launches for next year include balloon trocars, specimen retrieval bags, second-generation bipolar electrosurgical instruments, and a multifunctional electrosurgical irrigation and suction system, which are expected to provide new growth momentum.
In terms of global market expansion, LAGIS continues to strengthen its core European markets while actively expanding in Southeast Asia in recent years. In November 2025, the company successfully completed a robot-assisted radical prostatectomy (RARP) in Thailand using its single-port multi-channel trocar system in combination with the da Vinci Xi system, earning high recognition from the medical community and accelerating the adoption of natural orifice surgery across ASEAN markets. In the U.S., the company continues to advance product registrations and is in discussions with several major healthcare clients. As regulatory progress advances, the U.S. is expected to become one of the most explosive new markets in the medium term.
Driven by growing demand for minimally invasive surgery, LAGIS’s revenue has risen steadily from NT$300 million, reaching NT$454 million in 2024, the second-highest level in its history. Net profit after tax totaled NT$68.24 million, with EPS of NT$2.13. In the first three quarters of this year, revenue reached NT$364 million, a record high for the same period, with gross margin maintained above 47%, net profit after tax of NT$53.10 million, and EPS of NT$1.66.
Looking ahead to 2026, Chen said that stable growth from existing customers and the emergence of new regions will continue to drive performance. Southeast Asian markets such as Vietnam and Indonesia have seen rapid expansion in healthcare volumes in recent years and are gradually adopting minimally invasive surgery, becoming key new growth drivers. In addition, regions such as Guatemala in Central America, as well as the Middle East and North Africa, including Egypt, benefit from demographic dividends and hold significant potential. By advancing on multiple fronts—new products for existing customers, new customers, and new markets—the company aims to push revenue growth to double-digit percentages.
Resource: 微創手術廠常廣12月中旬上櫃，多引擎推升明年營運拚雙位數成長
